Oxbryta (Voxelotor)

Oxbryta is used in the management of sickle cell disease, a genetic disorder affecting hemoglobin.

• Sickle cell disease: Improves hemoglobin levels and reduces hemolysis.
• Sickle cell-related vaso‑occlusive crises: May lower the frequency of painful episodes.
• Chronic anemia in sickle cell disease: Contributes to better oxygen transport and quality of life.

• Voxelotor binds selectively to the N‑terminal valine of the hemoglobin beta chain, increasing its affinity for oxygen. This stabilises the oxygen‑loaded form of hemoglobin, reduces polymerisation of sickle hemoglobin (HbS), and thereby decreases red‑cell sickling and hemolysis.

Adverse reactions reported with Oxbryta are generally mild to moderate.

Common Side Effects

• Headache
• Diarrhea
• Nausea
• Fatigue
• Abdominal pain
• Dizziness

Serious or Rare Side Effects

• Liver enzyme elevation (ALT/AST)
• Severe allergic reactions (anaphylaxis)
• Hemolytic crisis
• Thromboembolic events
• Acute chest syndrome
• Severe rash or Stevens‑Johnson syndrome

Before using Oxbryta, consider the following safety measures:

• Monitor   :  Regular    ​      ​                                                                                                                                                                                                                            ​
• Contra‑indication :  Not  recommended  for  patients  with  severe  liver  impairment.
• Pregnancy  :  Use only if  the  potential  benefit  outweigh  the  risk  to  the  fetus.
• Breastfeeding :  Caution  due  to  potential  exposure  through  milk  but  data  limited.
• Drug interaction  :  Review  all  concomitant medications  for potential  pharmacokinetic  interactions.
• Store at below 25°C: keep  the  tablet  in  the  original  pack  and  protect  from  moisture.

• A             ... ... ... ...  
• a